Fibrin-fibrinogen and dethrombosis

Blood Coagulation and Fibrinolysis

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Muhlestein, J B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT;

ANIMAL; BLOOD; HUMAN; REVIEW; THROMBOSIS;

ANIMALS; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0033069376     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fuster V. Mechanisms of arterial thrombosis: foundation for therapy. Am Heart J 1998; 135: S361-S366.
2. Califf RM. Acute ischemic syndromes. Med Clin N Am 1995; 79: 999-1024.
3. Pifarre R. Thrombosis and cardiovascular disease. Med Clin N Am 1998; 82: 511-522.
4. Dang CV, Bell WR, Shuman M. The normal and morbid biology of fibrinogen. Am J Med 1989; 87: 567-576.
5. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
6. Braunwald E, Maseri A, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998; 19 (Suppl D): D22-D30.
7. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-1435.
8. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-443.
9. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-1497.
10. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-1646.
11. Brochier M, Raynaud P, Rioux P, Charbonnier B, Desveaux B, Pacouret G. Thrombosis and thrombolysis in unstable angina. Am J Cardiol 1991; 68: 105B-109B.
12. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. Circulation 1994; 90: 69-77.
13. Verheugt FW, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JG. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998; 31: 289-293.
14. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996; 93: 870-878.
15. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-671.
16. Wysokinski W, McBane R, Chesebro JH, Owen WG. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 1996; 76:1108-1113.
17. Parise LV, Phillips DR. Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem 1985; 260: 10698-10707.
18. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-535.
19. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. 'Rescue' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30: 1729-1734.
20. Garbaz E, Farah B, Vuillemenot A, et al. 'Rescue' abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 82: 800-803.
21. Russo G, Nicosia A, Tamburino C, Mammana C, Galassi AR, Monaco A, Grassi R, Calvi V, Giuffrida G. Dissolution of acute stent thrombosis by abciximab bolus. Cardiologia 1998; 43: 631-634.
22. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997; 95: 1755-1759.
23. Dangas G, Badimon JJ, Coller BS, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-1349.
24. Bell WR Jr. Defibrinogenating enzymes. Drugs 1997; 54 (Suppl 3): 18-30.